Objecting plaintiffs have formally filed a notice of appeal on Wednesday challenging the judicial decision issued by Judge Autrey. The... Read more
Tag: #Global Trends
GSK and Spero secure regulatory greenlight for Utebzi, the first oral carbapenem antibiotic for complicated UTIs
Four years after sustaining a regulatory rejection in 2022, British pharmaceutical giant GSK and its partner Spero Therapeutics have scored... Read more
Merck & Co. enters $510 million AI drug discovery pact with Stanford spinout Protillion Biosciences
Global biopharmaceutical giant Merck & Co. has finalized a strategic multi-year licensing and research collaboration agreement with Protillion Biosciences. The... Read more
FDA initiates review of Gilead’s once-weekly oral tablet for HIV PrEP application
The U.S. Food and Drug Administration (FDA) has officially commenced its formal regulatory review of Gilead Sciences’ once-weekly oral prescription... Read more
Hacking group claims 1.3 terabyte data breach at Novo Nordisk following failed $25 million extortion attempt
A cyber extortion group has claimed to have exfiltrated over a terabyte of proprietary data from Danish pharmaceutical behemoth Novo... Read more
FDA staff reviewers back Moderna’s flu shot data for accelerated older adult approval pathway
U.S. Food and Drug Administration staff reviewers announced on Tuesday that immunogenicity data tracking an active immune response to Moderna’s... Read more
Moderna eyes manufacturing investments in Germany, targeting BioNTech’s planned facility closures
Moderna Chief Executive Officer Stephane Bancel told the German business daily Handelsblatt on Wednesday (June 17, 2026) that the United... Read more
Edgewise heart drug clears Phase 2 trial milestone but faces investor skepticism over competitive edge
Colorado-based biotechnology firm Edgewise Therapeutics has announced that its investigational cardiovascular compound, EDG-7500, successfully met the primary objectives of its... Read more
Lilly’s Jaypirca combination slashes progression risk by 45% in pivotal Phase 3 BRUIN CLL-322 leukemia trial
Eli Lilly and Company has officially announced definitive data from its global Phase 3 BRUIN CLL-322 clinical trial. The landmark... Read more









